SoFi Web 3 ETF (TWEB)
- Previous Close
22.59 - Open
22.27 - Bid --
- Ask --
- Day's Range
21.78 - 22.27 - 52 Week Range
16.19 - 22.86 - Volume
2,626 - Avg. Volume
0 - Net Assets 2.52M
- NAV 21.90
- PE Ratio (TTM) --
- Yield 1.52%
- YTD Daily Total Return 2.85%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.59%
The index’s initial investible universe consists of equity securities listed on securities exchanges in the U.S., developed markets, and South Korea (the “Universe”). The Advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. It may invest in common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The fund’s investments may include small-, medium- and large-capitalization companies.
SoFi
Fund Family
Technology
Fund Category
2.52M
Net Assets
2022-08-08
Inception Date
Performance Overview: TWEB
Trailing returns as of 3/5/2024. Category is Technology.
Holdings: TWEB
Top 10 Holdings (47.49% of Total Assets)
Sector Weightings
Recent News: TWEB
Research Reports: TWEB
Raising target price to $23.00
RANGE RESOURCES CORP has an Investment Rating of SELL; a target price of $23.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetMerck Earnings: Solid Results Led by Keytruda and Gardasil as the Pipeline Makes Strong Progress
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice TargetRaising target price to $130.00
NOVANTA INC has an Investment Rating of SELL; a target price of $130.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $121.00
NOVANTA INC has an Investment Rating of SELL; a target price of $121.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target